Antibodies to TGF-Beta
AssigneesGenzyme Corporation, Optein, Inc.
InventorsSteven R. Ledbetter, Celia Patricia Hart, Robert G. Holgate, Lutz U. Jermutus, Catriona L. Buchanan, Alexander R. Duncan, Donna K. Finch
Life of this patent
Estimating the term…
Abstract
The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGFβ) and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGFβ1, TGFβ2 and TGFβ3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).
Claims17
1-63. (canceled)
A method of treating hepatic fibrosis or cirrhosis of the liver in a patient in need thereof, comprising administering to the patient an effective amount of an isolated specific binding member that binds to and neutralizes human TGFβ1, TGFβ2, and TGFβ3, the binding member comprising an antigen-binding domain of an antibody,
- wherein a heavy chain of the antibody comprises
- an HCDR1 comprising the amino acid sequence of SEQ ID NO:
- 3,
- an HCDR2 comprising the amino acid sequence of SEQ ID NO:
- 4, and
- an HCDR3 comprising the amino acid sequence of SEQ ID NO:
- 5;
- and
- wherein a light chain of the antibody comprises
- an LCDR1 comprising the amino acid sequence of SEQ ID NO:
- 8,
- an LCDR2 comprising the amino acid sequence of SEQ ID NO:
- 9, and
- an LCDR3 comprising the amino acid sequence of SEQ ID NO:
- 10.
A method of treating multiple sclerosis in a patient in need thereof, comprising administering to the patient an effective amount of an isolated specific binding member that binds to and neutralizes human TGFβ1, TGFβ2, and TGFβ3, the binding member comprising an antigen-binding domain of an antibody,
- wherein a heavy chain of the antibody comprises
- an HCDR1 comprising the amino acid sequence of SEQ ID NO:
- 3,
- an HCDR2 comprising the amino acid sequence of SEQ ID NO:
- 4, and
- an HCDR3 comprising the amino acid sequence of SEQ ID NO:
- 5;
- and
- wherein a light chain of the antibody comprises
- an LCDR1 comprising the amino acid sequence of SEQ ID NO:
- 8,
- an LCDR2 comprising the amino acid sequence of SEQ ID NO:
- 9, and
- an LCDR3 comprising the amino acid sequence of SEQ ID NO:
- 10.
Dependencies are inferred from the claim text.